Publications

• Negative 18F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.
  Clin Nucl Med
  06/06/2025 Authors: Lawal IO; Li X; Sakach EA; Farley CR; Meisel JL; Baum Y; Chaudhary KK; Wang Q; Torres MA; Mankoff DA
• Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).
  ESMO Open Volume: 10 Page(s): 105120
  06/04/2025 Authors: Naughton MJ; Zahrieh DM; Gnant M; Zdenkowski N; Lemieux J; Mao JJ; Bjelic-Radisic V; Shinn E; Balic M; Thomssen C
• Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
  Clin Breast Cancer Volume: 25 Page(s): 261 - 267.e1
  04/01/2025 Authors: Goldfarb SB; Sammons SL; Meisel JL; Pluard TJ; Jenkins SN; Komm BS; Carroll D; Portman DJ
• Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
  JCO Oncol Pract Volume: 21 Page(s): 351 - 357
  03/01/2025 Authors: Waks AG; Chen EL; Graham N; Frey AM; Almeida K; Attaya V; Ryding C; Abbass I; Fung A; Sussell J
• Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data.
  Ann Surg Oncol Volume: 32 Page(s): 2045 - 2055
  03/01/2025 Authors: Fefferman ML; Thompson DM; Wilke LG; Hwang S; Bleicher R; Freedman LM; Meisel JL; Kuchta K; Yao K
• ASO Visual Abstract: Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data.
  Ann Surg Oncol Volume: 32 Page(s): 2112 - 2113
  03/01/2025 Authors: Fefferman ML; Thompson DM; Wilke LG; Hwang S; Bleicher R; Freedman LM; Meisel JL; Kuchta K; Yao K
• Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
  Sci Rep Volume: 15 Page(s): 7220
  02/28/2025 Authors: Jones V; Yin HH; Yuan Y-C; Wang Y; Li SM; Aljaber D; Sanchez A; Quinones C; Schmolze D; Yuan Y
• Genomic and transcriptomic landscape of HER2-low breast cancer.
  Breast Cancer Res Treat Volume: 209 Page(s): 323 - 330
  01/01/2025 Authors: Bansal R; Adeyelu T; Elliott A; Walker P; Bustos MA; Rodriguez E; Accordino MK; Meisel J; Gatti-Mays ME; Hsu E
• Drug-drug interactions between palbociclib and proton pump inhibitors inearly breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
  ESMO Open Volume: 10 Page(s): 104096
  01/01/2025 Authors: Agostinetto E; Pfeiler G; Hlauschek D; Mayer EL; Lambertini M; de Azambuja E; Bellet-Ezquerra M; Meisel JL; Rubovszky G; Zdenkowski N
• TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-nave early-stage triple negative or HR-low/HER2- breast cancer.
  Ther Adv Med Oncol Volume: 17 Page(s): 17588359251316176
  01/01/2025 Authors: McArthur HL; Tolaney SM; Dent R; Schmid P; Asselah J; Liu Q; Meisel JL; Niikura N; Park YH; Werutsky G
• Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
  Nat Med Volume: 30 Page(s): 3728 - 3736
  12/01/2024 Authors: Khoury K; Meisel JL; Yau C; Rugo HS; Nanda R; Davidian M; Tsiatis B; Chien AJ; Wallace AM; Arora M
• Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
  JCO Precis Oncol Volume: 8 Page(s): e2400289
  12/01/2024 Authors: Bansal R; Adeyelu T; Elliott A; Tan AR; Ribeiro JR; Meisel J; Oberley MJ; Graff SL; Sledge GW; Grilley-Olson JE
• Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
  Eur J Nucl Med Mol Imaging Volume: 51 Page(s): 4073 - 4082
  11/01/2024 Authors: Mushtaq A; Lawal IO; Muzahir S; Friend SC; Bhave M; Meisel JL; Torres MA; Styblo TM; Graham CL; Kalinsky K
• Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.
  JCO Oncol Pract Volume: 20 Page(s): 1376 - 1383
  10/01/2024 Authors: Graetz I; Hernandez S; Arshad S; Byers K; Meisel J; Sadigh G; Sakach EA; Gogineni K; Torres MA
• PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
  J Clin Oncol Volume: 42 Page(s): 2050 - 2060
  06/10/2024 Authors: Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y
• High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
  Breast Cancer Res Treat Volume: 205 Page(s): 193 - 199
  05/01/2024 Authors: Wood SJ; Gao Y; Lee J-H; Chen J; Wang Q; Meisel JL; Li X
• Correlation of HER2 Protein Level With mRNA Level Quantified byRNAscope in Breast Cancer.
  Mod Pathol Volume: 37 Page(s): 100408
  02/01/2024 Authors: Li X; Lee J-H; Gao Y; Zhang J; Bates KM; Rimm DL; Zhang H; Smith GH; Lawson D; Meisel J
• Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study.
  J Oncol Pharm Pract Volume: 29 Page(s): 1957 - 1964
  12/01/2023 Authors: Sadigh G; Meisel JL; Byers K; Robles A; Serrano L; Jung OS; Coleman D; Yeager KA; Graetz I
• Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
  Volume: 41 Page(s): 5118 - 5130
  11/20/2023 Authors: Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M
• Percutaneous CT-Guided Cryoneurolysis of the Intercostobrachial Nerve for Management of Postmastectomy Pain Syndrome.
  J Vasc Interv Radiol Volume: 34 Page(s): 807 - 813
  05/01/2023 Authors: Nezami N; Behi A; Manyapu S; Meisel JL; Resnick N; Corn D; Prologo JD
• Using Oncotype DX breast recurrence score assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
  Breast Cancer Res Treat Volume: 199 Page(s): 91 - 98
  05/01/2023 Authors: Taylor C; Meisel J; Foreman AJ; Russell C; Bandyopadhyay D; Deng X; Floyd L; Zelnak A; Bear H; O'Regan R
• A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment.
  Clin Nucl Med Volume: 48 Page(s): e202 - e203
  04/01/2023 Authors: Adediran OA; Lawal IO; Muzahir S; Bhave MA; Friend S; Fielder B; Meisel J; Torres MA; Styblo TM; Graham C
• Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
  Gynecol Oncol Volume: 170 Page(s): 93 - 101
  03/01/2023 Authors: Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y
• When the personal becomes political: The impact of the Dobbs decision on women with cancer.
  Cancer Volume: 129 Page(s): 171 - 174
  01/15/2023 Authors: Meisel JL; Harrington A; Whaley N; Vitek W; O'Regan RM
• A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.
  Clin Nucl Med Volume: 48 Page(s): e26 - e27
  01/01/2023 Authors: Lawal IO; Adediran OA; Muzahir S; Friend S; Bhave MA; Meisel J; Torres MA; Styblo TM; Graham C; Holbrook A
• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, earlybreast cancer.
  Ann Oncol Volume: 33 Page(s): 1250 - 1268
  12/01/2022 Authors: Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G
• Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).
  Cardiovasc Intervent Radiol Volume: 45 Page(s): 1725 - 1734
  11/01/2022 Authors: Wu R; Gogineni K; Meisel J; Szabo S; Thirunavu M; Friend S; Bercu Z; Sethi I; Natarajan N; Switchenko J
• Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.
  Gynecol Oncol Rep Volume: 43 Page(s): 101062
  10/01/2022 Authors: Carballo EV; Pham TV; Turashvili G; Hanley K; Starbuck KD; Meisel JL
• Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.
  Public Health Genomics Page(s): 1 - 14
  08/09/2022 Authors: Rose E; Hardy MW; Gates R; Stanislaw C; Meisel J; Grinzaid KA
• Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials.
  J Cancer Educ Volume: 37 Page(s): 387 - 394
  04/01/2022 Authors: Yeager KA; Bai J; Gogineni K; Meisel JL; Kweon J; Bruner DW; Waldrop-Valverde D
• Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
  Breast Cancer Res Treat Volume: 192 Page(s): 509 - 516
  04/01/2022 Authors: Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
• Correlates of financial toxicity in adult cancer patients and their informal caregivers.
  Support Care Cancer Volume: 30 Page(s): 217 - 225
  01/01/2022 Authors: Sadigh G; Switchenko J; Weaver KE; Elchoufi D; Meisel J; Bilen MA; Lawson D; Cella D; El-Rayes B; Carlos R
• Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
  Ther Adv Med Oncol Volume: 14 Page(s): 17588359221084769
  01/01/2022 Authors: Taylor C; Meisel J; Kalinsky K
• Case report of lymph node activation mimicking cancer progression: A false positive F18 FDG PET CT after COVID-19 vaccination.
  Curr Probl Cancer Case Rep Volume: 4 Page(s): 100092
  12/01/2021 Authors: Schapiro R; Moncayo VM; Meisel JL
• Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
  Clin Breast Cancer Volume: 21 Page(s): 509 - 520
  12/01/2021 Authors: Sakach E; O'Regan R; Meisel J; Li X
• Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
  Int J Gynecol Pathol Volume: 40 Page(s): 501 - 509
  09/01/2021 Authors: Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
• We have to talk about it: Bringing fertility into the conversation for young women with breast cancer.
  Cancer Volume: 127 Page(s): 2873 - 2876
  08/15/2021 Authors: Taylor CE; Meisel JL
• Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.
  J Clin Oncol Volume: 39 Page(s): 1165 - 1184
  04/01/2021 Authors: Smith SM; Wachter K; Burris HA; Schilsky RL; George DJ; Peterson DE; Johnson ML; Markham MJ; Mileham KF; Beg MS
• Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer.
  Cancer Volume: 127 Page(s): 834 - 836
  03/15/2021 Authors: Taylor CE; Meisel JL
• The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.
  Clin Breast Cancer Volume: 20 Page(s): e701 - e710
  12/01/2020 Authors: Escott CE; Zaenger D; Switchencko JM; Lin JY; Abugideiri M; Arciero CA; Pfister NT; Xu KM; Meisel JL; Subhedar P
• HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
  Pathol Res Pract Volume: 216 Page(s): 153155
  11/01/2020 Authors: Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
• The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology.
  J Cancer Educ Volume: 35 Page(s): 864 - 870
  10/01/2020 Authors: McDaniels BA; Hianik RS; Bellcross C; Shaib WL; Switchenko J; Dixon MD; Meisel JL; Gogineni K; Pentz RD
• Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+and FOXP3+immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
  Breast Cancer Res Treat Volume: 183 Page(s): 599 - 606
  10/01/2020 Authors: Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
• Optimizing the Duration of Trastuzumab: A Fresh Perspective.
  Oncology (Williston Park) Volume: 34 Page(s): 296 - 301
  08/12/2020 Authors: Taylor MA; Byers KF; Meisel JL
• Assessing the Impact of TAILORx on Breast Cancer Management
  ONCOLOGY-NEW YORK Volume: 34 Page(s): 224 - 226
  06/01/2020 Authors: Meisel JL
• Gemcitabine with carboplatin in metastatic breast cancer: Characterizing outcomes in a modern, real-world population.
  Volume: 38
  05/20/2020 Authors: Higgins JP; Lalonde C; Byers KF; Davis C; Horne K; Goyal S; Chen Z; Meisel JL; Kramer JL; Barbee MS
• Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
  J Clin Oncol Volume: 38 Page(s): 1081
  04/01/2020 Authors: Markham MJ; Wachter K; Agarwal N; Bertagnolli MM; Chang SM; Dale W; Diefenbach CSM; Rodriguez-Galindo C; George DJ; Gilligan TD
• Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
  Clin Breast Cancer Volume: 20 Page(s): 19 - 24
  02/01/2020 Authors: Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R
• Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
  Volume: 80
  02/01/2020 Authors: Onishi N; Li W; Newitt DC; Harnish R; Gibbs J; Jones EF; Nguyen A; Wilmes L; Joe BN; Campbell MJ
• The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
  Volume: 80
  02/01/2020 Authors: Li W; Onishi N; Newitt DC; Harnish R; Jones EF; Wilmes LJ; Gibbs J; Price E; Joe BN; Chien AJ
• Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
  Volume: 80
  02/01/2020 Authors: Li W; Onishi N; Newitt DC; Gibbs J; Wilmes LJ; Jones EF; Joe BN; Sit LS; Yau C; Chien AJ
• Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints
  Volume: 80
  02/01/2020 Authors: Yau C; DeMichele A; Symmans WF; Pusztai L; Yee D; Clark AS; Hatzis C; Matthews JB; Carter J; Chen Y-Y
• Race, breast cancer, and prognosis: Where biology is queen?
  Cancer Volume: 125 Page(s): 3104 - 3106
  09/15/2019 Authors: Meisel JL; O'Regan RM
• A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
  Breast Cancer Res Volume: 21 Page(s): 100
  09/02/2019 Authors: Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J
• The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients.
  Volume: 37
  05/20/2019 Authors: Patel U; Meisel JL; Barbee MS; Frinzi K; Sakach E; Chen Z
• HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 32
  03/01/2019 Authors: Zhao J; Meisel J; Suo A; Zhang C; Wei Z; Aneja R; Li Z; Nahta R; Li X
• Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
  Volume: 99
  03/01/2019 Authors: Zhao J; Meisel J; Suo A; Zhang C; Wei Z; Aneja R; Li Z; Nahta R; Li X
• Evaluation of tumor infiltrating lymphocyte, CD8+and FOXP3+cells and PD-L1 expression in tumor response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 32
  03/01/2019 Authors: Li X; Zhao J; Guo Y; Schneider F; Peng L; Aneja R; Meisel J; Nahta R
• Evaluation of tumor infiltrating lymphocyte, CD8+and FOXP3+cells and PD-L1 expression in tumor response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 99
  03/01/2019 Authors: Li X; Zhao J; Guo Y; Schneider F; Peng L; Aneja R; Meisel J; Nahta R
• Care 001: multi-center randomized open-label phase II trial of neoadjuvant trastuzumab emtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER2-neu over-expressed breast cancer patients (TEAL study)
  Volume: 79
  02/01/2019 Authors: Creamer SL; Patel TA; Ensor JE; Rodriguez AA; Niravath PA; Darcourt JG; Kaklamani VG; Meisel JL; Li X; Zhao J
• Clinicopathologic factors associated with pCR to neoadjuvant anti-HER2-directed chemotherapy
  Volume: 79
  02/01/2019 Authors: Meisel JL; Suo A; Taylor CE; Zhang C; Li X
• Breast Cancer and Heart Failure.
  Heart Fail Clin Volume: 15 Page(s): 65 - 75
  01/01/2019 Authors: Almuwaqqat Z; Meisel JL; Barac A; Parashar S
• A Big World Made Small: Using Social Media to Optimize Patient Care.
  Am Soc Clin Oncol Educ Book Volume: 39 Page(s): e212 - e218
  01/01/2019 Authors: Subbiah IM; Hamilton E; Knoll M; Shanahan K; Meisel J
• Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.
  Clin Breast Cancer Volume: 18 Page(s): 347 - 352
  10/01/2018 Authors: Meisel J; Zhang C; Neely C; Mendoza P; You S; Han T; Liu Y; Sahin AA; O'Regan R; Li X
• Pathologic Characteristics of Node-Positive Invasive Breast Carcinomas Associated With Extranodal Extension
  Volume: 150 Page(s): S53 - S53
  10/01/2018 Authors: Wade J; Little J; Zhang C; Chen Z; Meisel J; Hanley K
• Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
  Breast Cancer Res Treat Volume: 171 Page(s): 303 - 313
  09/01/2018 Authors: Li X; Zhang Y; Meisel J; Jiang R; Behera M; Peng L
• Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer.
  Oncology (Williston Park) Volume: 32 Page(s): 392 - 417
  08/15/2018 Authors: Arciero C; Thompson P; Meisel JL; Taylor CE; Torres MA; Wood WC
• Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.
  Am Soc Clin Oncol Educ Book Volume: 38 Page(s): 78 - 86
  05/23/2018 Authors: Meisel JL; Venur VA; Gnant M; Carey L
• Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study)
  Volume: 36
  05/20/2018 Authors: Patel TA; Ensor J; Creamer S; Rodriguez AA; Niravath PA; Darcourt JG; Kaklamani VG; Meisel JL; Li X; Kuhn JG
• Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
  Clin Cancer Res Volume: 23 Page(s): 6708 - 6720
  11/01/2017 Authors: Weigelt B; Comino-Mndez I; de Bruijn I; Tian L; Meisel JL; Garca-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY
• Management of Breast Cancer Therapy-Related Sexual Dysfunction.
  Oncology (Williston Park) Volume: 31 Page(s): 726 - 729
  10/15/2017 Authors: Taylor CE; Meisel JL
• The Influence of Histologic Grade on Outcomes of Elderly Women with Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiation Therapy
  Volume: 99 Page(s): E59 - E59
  10/01/2017 Authors: Zaenger D; Madden NA; Tanenbaum DG; Abugideiri M; Lin JY; Switchenko J; Meisel J; Subhedar P; Arciero C; Torres M
• Wilms' tumor of the ovary.
  Gynecol Oncol Rep Volume: 19 Page(s): 18 - 21
  02/01/2017 Authors: Alexander VM; Meisel J; O'Brien S; Khanna N
• Triple Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival Than Non-Triple Negative Breast Cancer
  Volume: 97 Page(s): 54A - 54A
  02/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• Triple Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival Than Non-Triple Negative Breast Cancer
  Volume: 30 Page(s): 54A - 54A
  02/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)
  Volume: 77
  02/01/2017 Authors: Paplomata E; Gogineni K; Meisel J; Santa-Maria C; Yuan L; Kramer J; Li XB; Zelnak A; Pakkala S; Kaklamani V
• Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
  Breast Cancer Res Treat Volume: 161 Page(s): 279 - 287
  01/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• For Our Patients, for Ourselves: The Value of Personal Reflection in Oncology.
  Am Soc Clin Oncol Educ Book Volume: 37 Page(s): 765 - 770
  01/01/2017 Authors: Schapira L; Meisel JL; Srivastava R
• Prevention and Screening in Hereditary Breast and Ovarian Cancer.
  Oncology (Williston Park) Volume: 30 Page(s): 896 - 904
  10/15/2016 Authors: Zeichner SB; Stanislaw C; Meisel JL
• Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
  Am J Clin Pathol Volume: 146 Page(s): 496 - 502
  10/01/2016 Authors: Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C
• Development of a risk stratification system to guide treatment for female germ cell tumors.
  Volume: 138 Page(s): 566 - 572
  09/01/2015 Authors: Meisel JL; Woo KM; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Gardner GJ; Bosl GJ; Aghajanian C
• The role of systemic chemotherapy in the management of granulosa cell tumors.
  Gynecol Oncol Volume: 136 Page(s): 505 - 511
  03/01/2015 Authors: Meisel JL; Hyman DM; Jotwani A; Zhou Q; Abu-Rustum NR; Iasonos A; Pike MC; Aghajanian C
• The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
  Ann Oncol Volume: 25 Page(s): 2372 - 2378
  12/01/2014 Authors: Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M
• Sentinel lymph node biopsy in pregnant women with breast cancer.
  Ann Surg Oncol Volume: 21 Page(s): 2506 - 2511
  08/01/2014 Authors: Gropper AB; Calvillo KZ; Dominici L; Troyan S; Rhei E; Economy KE; Tung NM; Schapira L; Meisel JL; Partridge AH
• Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience.
  Volume: 32
  05/20/2014 Authors: Meisel JL; Woo K; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Motzer RJ; Bosi GJ; Aghajanian C
• Contemporary multidisciplinary treatment of pregnancy-associated breast cancer.
  Springerplus Volume: 2 Page(s): 297
  12/01/2013 Authors: Meisel JL; Economy KE; Calvillo KZ; Schapira L; Tung NM; Gelber S; Kereakoglow S; Partridge AH; Mayer EL
• Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer (PABC).
  Volume: 31
  05/20/2013 Authors: Gropper A; Calvillo KZ; Troyan S; Dominici LS; Rhei E; Economy KE; Schapira L; Tung NM; Meisel JL; Partridge AH
• Immediate tissue expander breast reconstruction following mastectomy hi pregnancy-associated breast cancer.
  Volume: 31
  05/20/2013 Authors: Calvillo KZ; Caragacianu DL; Chun YS; Caterson S; Bellon JR; Wong JS; Troyan S; Rhei E; Dominici LS; Economy KE
• Quality of life in long-term survivors of metastatic breast cancer.
  Clin Breast Cancer Volume: 12 Page(s): 119 - 126
  04/01/2012 Authors: Meisel JL; Domchek SM; Vonderheide RH; Giobbie-Hurder A; Lin NU; Winer EP; Partridge AH
• Multidisciplinary Treatment of Pregnancy-Associated Breast Cancer.
  Volume: 71
  12/15/2011 Authors: Meisel JL; Economy KE; Zabicki-Calvillo K; Gelber S; Kereakoglow S; Winer EP; Partridge AH; Mayer EL